Turn Therapeutics Inc.
TTRX
$6.93
$0.111.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 323.37% | 277.60% | 136.82% | 69.21% | -22.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 340.38% | 261.15% | 115.45% | 71.69% | -11.52% |
| Operating Income | -340.38% | -261.15% | -115.45% | -71.69% | 11.52% |
| Income Before Tax | -129.74% | -84.54% | -108.00% | -62.32% | 14.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -129.74% | -84.54% | -108.00% | -62.32% | 14.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -129.74% | -84.54% | -108.00% | -62.32% | 14.49% |
| EBIT | -340.38% | -261.15% | -115.45% | -71.69% | 11.52% |
| EBITDA | -349.71% | -268.10% | -117.80% | -72.86% | 12.12% |
| EPS Basic | -118.08% | -77.85% | -99.71% | -58.22% | 15.31% |
| Normalized Basic EPS | -118.46% | -77.83% | -100.00% | -58.76% | 15.22% |
| EPS Diluted | -118.08% | -77.85% | -99.71% | -58.22% | 15.31% |
| Normalized Diluted EPS | -118.46% | -77.83% | -100.00% | -58.76% | 15.22% |
| Average Basic Shares Outstanding | 5.92% | 4.01% | 3.03% | 1.92% | 0.99% |
| Average Diluted Shares Outstanding | 5.92% | 4.01% | 3.03% | 1.92% | 0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |